« Back
Home /
LDN193189

LDN193189

Item no.	HY-12071-50mg
Manufacturer	MedChem Express
CASRN	1062368-24-4
Amount	50 mg
Quantity options	10mM/1mL 10 mg 50 mg 5 mg
Category	Oncology Neuroscience Molecular Targets for Neuroscience Inhibitors & Compound Libraries Small Molecules By Organ Skin Cancer
Type	Inhibitors
Specific against	other
Purity	99.48
Formula	C25H22N6
Citations	Adv Sci (Weinh). 2024 Jan 18:e2308072.<br>Biochim Biophys Acta Gen Subj. 29 October 2021, 130046.<br>Biomaterials. 2020 May;240:119849.<br>bioRxiv. 2024 Mar 13.<br>bioRxiv. 2024 Mar 25.<br>Cancer Metab. 2023 Jul 13;11(1):9.<br>Cardiovasc Toxicol. 2019 Jun;19(3):264-275. <br>Cell Rep Methods. 2024 May 8:100777.<br>Cell Rep. 2023 Dec 5;42(12):113541.<br>EMBO Rep. 2023 Jul 26;e56454.<br>Eur Respir J. 2021 Dec 2;2100327.<br>Exp Ther Med. 2019 Apr;17(4):2648-2656. <br>Front Cell Dev Biol. 13 May 2021.<br>Front Mol Biosci. 2021 Apr 26;8:663987.<br>Front Mol Biosci. 2021; 8: 663987.<br>Int J Mol Sci. 2022, 23(23), 14831.<br>Int J Mol Sci. 2024 Apr 9, 25(8), 4138.<br>Int J Ophthalmol. 2022 May 18;15(5):711-720.<br>iScience. 2019 Sep 27;19:1248-1259.<br>iScience. 2022 Dec 26;26(1):105898.<br>iScience. 2024 Feb 5;27(3):109111.<br>J Hazard Mater. 2023 Nov 19, 133028.<br>J Recept Signal Transduct Res. 2017 Oct;37(5):515-521.<br>Mar Drugs. 2022 Nov 14;20(11):715.<br>Mol Cell. 2022 Jun 3;S1097-2765(22)00480-4.<br>Oxid Med Cell Longev. 2020 Jun 8;2020:4175613.<br>Patent. US20210346386A1.<br>Pigment Cell Melanoma Res. 2023 Aug 9.<br>Research Square Preprint. 2021 Sep.<br>Research Square Preprint. 2023 May 17.<br>Sci Rep. 2022 Mar 18;12(1):4740.<br>Sci Rep. 2022 Mar 25;12(1):5221.<br>Stem Cell Res Ther. 2022 Aug 19;13(1):424.<br>Stem Cell Res Ther. 2022 Sep 2;13(1):436.<br>Stem Cell Res Ther. 2023 Jan 5;14(1):1.<br>Stem Cells Int. 2022 Apr 28;2022:1560943.<br>Stem Cells Int. 22 Dec 2022.<br>Stem Cells. 2023 Apr 8;sxad028.<br>Transl Oncol. 2019 Dec 19;13(2):125-134<br>Cancer Lett. 2020 Jan 28;469:390-398.<br>Cell Rep. 2017 Aug 29;20(9):2227-2237. <br>Cell Rep. 2017 Aug 29;20(9):2227-2237. <br>Curr Protoc Cell Biol. 2018 Dec;81(1):e62.<br>Diabetes. 2020 Apr;69(4):634-646.<br>EMBO Rep. 2023 Jul 26;e56454.<br>Harvard Medical School LINCS LIBRARY<br>Nature. 2022 May;605(7909):325-331.<br>Patent. US20180263995A1.<br>Prostate. 2021 Sep 23.<br>Stem Cell Res Ther. 2021 Jun 11;12(1):345.<br>[1]Daniel Horbelt, et al. Small molecules dorsomorphin and LDN-193189 inhibit myostatin/GDF8 signaling and promote functional myoblast differentiation. J Biol Chem. 2015 Feb 6;290(6):3390-404.<br>[2]Julien Vollaire, et al. The Bone Morphogenetic Protein Signaling Inhibitor LDN-193189 Enhances Metastasis Development in Mice. Front Pharmacol. 2019 Jun 19;10:667. <br>[3]Yu PB, et al. BMP type I receptor inhibition reduces heterotopic [corrected] ossification. Nat Med, 2008, 14(12), 1363-1369.
Smiles	C1(C2=C3N=CC(C4=CC=C(N5CCNCC5)C=C4)=CN3N=C2)=CC=NC6=CC=CC=C16
ECLASS 5.1	30220300
ECLASS 6.1	30220300
ECLASS 8.0	32160605
ECLASS 9.0	32160605
ECLASS 10.0.1	32160490
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	DM-3189
Available
Product Description	LDN193189 is a potent selective BMP type I receptor (BMP I) inhibitor. LDN-193189 efficiently inhibits transcriptional activity of the BMP type I receptors ALK2 and ALK3 with IC50 values of 5 nM and 30 nM, respectively. LDN-193189 can be used for the research of bone morphogenetic protein signalling, such as fibrodysplasia ossificans progressiva[1][2][3].
StorageTemperature	-20°C, 3 years; 4°C, 2 years (Powder)
Shipping	Room Temperature
Manufacturers Applications	Cancer-Kinase/protease
MolecularWeight	406.48
Clinical_Information	No Development Reported
Manufacturers Research Area	Cancer
Solubility	DMSO : 10 mg/mL (ultrasonic; warming; adjust pH to 2 with 1M HCl; heat to 80°C)\|H2O : < 0.1 mg/mL
Manufacturers Target	Organoid; TGF-β Receptor
Isoform	ALK2; ALK3
Pathway	Stem Cell/Wnt; TGF-beta/Smad

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-12071-50mg-safety-datasheet.pdf